Biogen adds real-world test for Aduhelm to its confirmatory trialBiogen and partner Eisai have said they will run a large-scale observational study of Alzheimer’s drug Aduhelm in Share XBiogen adds real-world test for Aduhelm to its confirmatory trialhttps://pharmaphorum.com/news/biogen-adds-real-world-test-for-aduhelm-to-its-confirmatory-trial/
FDA staffers defend Aduhelm approval in JAMA editorialThree FDA figures at the centre of the fallout over the approval Biogen and Eisai’s Alzheimer’s disease therapy Share XFDA staffers defend Aduhelm approval in JAMA editorialhttps://pharmaphorum.com/news/fda-staffers-defend-aduhelm-approval-in-jama-editorial/
Amid outcry over Aduhelm price, Biogen says it may consider ‘adjustment’Biogen has hinted that it may consider altering the price of its controversially-approved Alzheimer’s therapy Aduhelm – but Share XAmid outcry over Aduhelm price, Biogen says it may consider ‘adjustment’https://pharmaphorum.com/news/amid-outcry-over-aduhelm-price-biogen-says-it-may-consider-adjustment/
Consumer group seeks resignation of top FDA staffers over Aduhelm okayWith the first patient set to receive Biogen’s new Alzheimer’s drug Aduhelm in Rhode Island today, US consumer Share XConsumer group seeks resignation of top FDA staffers over Aduhelm okayhttps://pharmaphorum.com/news/consumer-group-seeks-resignation-of-top-fda-staffers-over-aduhelm-okay/
And then there were three: another FDA adcomm member quits over AduhelmThe fallout over the FDA’s decision to approved Biogen’s Alzheimer’s therapy Aduhelm continues to be felt, with a Share XAnd then there were three: another FDA adcomm member quits over Aduhelmhttps://pharmaphorum.com/news/and-then-there-were-three-another-fda-adcomm-member-quits-over-aduhelm/
Double resignation over Aduhelm approval depletes FDA’s CNS adcommTwo members of an FDA advisory committee have now resigned in protest over Monday’s approval of Biogen’s Alzheimer’s Share XDouble resignation over Aduhelm approval depletes FDA’s CNS adcommhttps://pharmaphorum.com/news/double-resignation-over-aduhelm-approval-depletes-fdas-cns-adcomm/
FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tagThe FDA “has failed in its responsibility to protect patients and families from unproven treatments with known harms” Share XFDA slammed over Aduhelm OK as Biogen takes heat for $56k price taghttps://pharmaphorum.com/news/fda-slammed-over-aduhelm-ok-as-biogen-takes-heat-for-56k-price-tag/
Jubilation for Biogen, Eisai as FDA says ‘yes’ to aducanumabBiogen and Eisai have defied the naysayers and secured an historic FDA approval for their amyloid-targeting antibody aducanumab Share XJubilation for Biogen, Eisai as FDA says ‘yes’ to aducanumabhttps://pharmaphorum.com/news/jubilation-at-biogen-as-fda-says-yes-to-aducanumab/
FDA grew too close to Biogen during Alzheimer’s drug development, doctors sayThe FDA got too close to Biogen during the development of the Alzheimer’s drug aducanumab, according to its Share XFDA grew too close to Biogen during Alzheimer’s drug development, doctors sayhttps://pharmaphorum.com/news/fda-grew-too-close-to-biogen-during-alzheimers-drug-development-doctors-say/
